Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1701 with BP102 and XELOX in mCRC
NCT04856787Phase 3Terminated
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Jun 2021
- Primary completion
- Apr 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of retlirafusp alfa in metastatic colorectal cancer (mCRC) (3 arms), sponsored by Suzhou Suncadia Biopharmaceutical. Primary endpoints: Objective Response Rate up to 2 years, Incidence of Adverse Events up to 2 years and 1 more. Started Jun 2021; status: terminated.
02
Drugs
retlirafusp alfa
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT04856787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04856787.